Valuation: Geron Corporation

Market Cap 815M 715M 658M 614M 1.16B 77.46B 1.18B 7.92B 3.07B 38.02B 3.06B 2.99B 132B P/E 2026 *
-63.5x
P/E 2027 * 19.5x
Enterprise Value 794M 697M 641M 598M 1.13B 75.47B 1.15B 7.72B 2.99B 37.04B 2.98B 2.92B 129B EV / Sales 2026 *
3.4x
EV / Sales 2027 * 1.94x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day-0.78%
1 week-8.30%
Current month-0.78%
1 month+4.96%
3 months-23.49%
6 months-3.79%
Current year-3.79%
1 week 1.26
Extreme 1.26
1.41
1 month 1.08
Extreme 1.08
1.47
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 07/08/2025
Director of Finance/CFO 59 25/09/2023
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 76 21/05/2010
Director/Board Member 72 28/09/2012
Director/Board Member 55 26/03/2019
Date Insider Type Main position Quantity % Market Cap.
20/05Free

Director

220,000 0.0343%
20/05Free

Director

220,000 0.0343%
20/05Free

Chairman

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
-0.78%-8.30%-7.97%-60.44% 815M
+1.81%+3.33%+72.68%+131.20% 56.21B
+0.55%+8.49%+77.09%+100.93% 55.38B
+0.93%+4.11%-12.64%-12.98% 23.75B
+0.36%+3.42%+9.61%+407.11% 23.19B
+3.64%+8.34%+39.81%-5.88% 18.14B
+0.89%+5.43%+40.01%-30.02% 16.84B
+1.49%+17.24%+174.91%+344.55% 15.86B
-0.83%+2.06%+23.70%+182.37% 13.56B
+7.20%+13.33%+42.13% - 12.97B
Average +1.52%+5.72%+45.93%+117.43% 23.67B
Weighted average by Cap. +1.47%+6.56%+56.22%+131.28%

Financials

2026 *2027 *
Net sales 234M 205M 189M 176M 332M 22.22B 339M 2.27B 880M 10.91B 878M 859M 37.96B 333M 292M 269M 251M 473M 31.67B 483M 3.24B 1.25B 15.55B 1.25B 1.22B 54.11B
Net income -13.95M -12.25M -11.28M -10.51M -19.82M -1.33B -20.22M -136M -52.55M -651M -52.39M -51.26M -2.27B 46.55M 40.87M 37.62M 35.05M 66.11M 4.43B 67.45M 452M 175M 2.17B 175M 171M 7.56B
Net Debt -20.97M -18.41M -16.95M -15.79M -29.78M -1.99B -30.39M -204M -78.97M -979M -78.73M -77.03M -3.41B -169M -148M -137M -127M -240M -16.07B -245M -1.64B -636M -7.89B -635M -621M -27.45B
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
02/07/26 USD 1.284 +1.10% 509,632
01/07/26 USD 1.270 -0.78% 9,923,008
30/06/26 USD 1.280 -1.54% 12,592,432
29/06/26 USD 1.300 -1.52% 14,561,547
26/06/26 USD 1.320 -3.65% 36,634,117
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.270USD
Average target price
3.400USD
Spread / Average Target
+167.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GERN Stock